Australia markets open in 7 hours 39 minutes

Waters Corporation (WAT)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
306.14-4.11 (-1.32%)
As of 12:21PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close310.25
Open309.28
Bid305.80 x 1100
Ask306.39 x 800
Day's range303.87 - 307.33
52-week range231.90 - 363.80
Volume84,385
Avg. volume414,151
Market cap18.157B
Beta (5Y monthly)0.96
PE ratio (TTM)28.27
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date26 Nov 1996
1y target estN/A
  • PR Newswire

    Waters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns

    Waters Corporation (NYSE:WAT) today introduced new GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron (3 µm) Columns. Waters has implemented a unique combination of novel packing materials and MaxPeak™ Premier High-Performance Surface (HPS) technology into the columns to help scientists accelerate the development of gene-based therapeutics, including cell & gene, mRNA and LNPs.

  • PR Newswire

    Waters Corporation Schedules First Quarter 2024 Earnings Conference Call

    Waters Corporation (NYSE:WAT) will hold its Q1 2024 financial results conference call live on Tuesday, May 7th, 2024 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 4th, 2024, at midnight Eastern Time.

  • PR Newswire

    Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors

    Analytica 2024 -- Waters Corporation (NYSE:WAT) today announced the launch of the Alliance iS Bio HPLC System with new capabilities that address the operational and analytical challenges of biopharma quality control (QC) laboratories. The new HPLC system combines advanced bio-separation technology and built-in instrument intelligence features. It is designed to help biopharma QC analysts boost efficiency and eliminate up to 40% of common errors, saving time lost by investigating the source of fa